Hepatic toxicity associated with gold therapy.
Three patients with rheumatoid arthritis developed jaundice after initiation of chrysotherapy. Gold sodium thiomalate had been administered in dosages of 37.5, 60, and 110 mg in these patients before the onset of jaundice. Liver function studies indicated a cholestatic jaundice in all subjects. One patient underwent exploratory laparotomy because of progressive jaundice. Liver biopsy was done in two patients. In one patient significant bile stasis and thrombi were seen in the biliary tree. In another patient liver biopsy showed ballooning of hepatocytes with minimal cholestasis. All patients recovered spontaneously. Awareness of this rare complication may prevent unnecessary diagnostic and surgical procedures in patients with rheumatoid arthritis who may develop jaundice while receiving chrysotherapy.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001707:Biopsy, Needle; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D002779:Cholestasis / Q000139:chemically induced / Q000473:pathology; D005260:Female; D006052:Gold Sodium Thiomalate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007565:Jaundice / Q000139:chemically induced* / Q000473:pathology; D008099:Liver / Q000187:drug effects*; D008875:Middle Aged
D006052:Gold Sodium Thiomalate